Sign inCreate account

Report workspace

Add to folder
NCT06686173NOT_YET_RECRUITINGanonymous

The Effect of the Parous Female and Young Male Donor on the Outcomes of GVHD Prophylaxis Underwent the Combined Treatment of ATG and PTCy for Haplo-HSCT: a Prospective, Multi-center, Cohort Study

Sponsor

Source record

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase

Source record

Not yet recruiting

Modality

AI-normalized

combination therapy

Target

AI-normalized

Graft-versus-host disease (GVHD) prophylaxis through the combination of antithymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) in haploidentical peripheral blood stem cell transplantation (haplo-HSCT).

Indication / condition

AI-normalized

High-Risk Acute Myeloid Leukemia

Intervention

Source record

None-placebo, non-intervention study, donor selection

Source & freshness

Source record

NCT ID

NCT06686173

Original source

ClinicalTrials.gov

Source last updated

Jan 07, 2025

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06686173

Title

The Effect of the Parous Female and Young Male Donor on the Outcomes of GVHD Prophylaxis Underwent the Combined Treatment of ATG and PTCy for Haplo-HSCT: a Prospective, Multi-center, Cohort Study

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Status

NOT_YET_RECRUITING

Phase

Not yet recruiting

Condition raw

High-Risk Acute Myeloid Leukemia, Relapse And/or Refractory AML

Condition normalized

High-Risk Acute Myeloid Leukemia, Relapse And/or Refractory AML

Modality raw

combination therapy

Modality normalized

combination therapy

Target raw

Graft-versus-host disease (GVHD) prophylaxis through the combination of antithymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) in haploidentical peripheral blood stem cell transplantation (haplo-HSCT).

Target normalized

Graft-versus-host disease (GVHD) prophylaxis through the combination of antithymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) in haploidentical peripheral blood stem cell transplantation (haplo-HSCT).

Interventions

None-placebo, non-intervention study, donor selection

Public preview

Source record

This prospective, multicenter cohort study sponsored by Shanghai General Hospital aims to evaluate the impact of donor characteristics (parous female vs. young male) on GVHD prophylaxis outcomes in high-risk acute myeloid leukemia (AML) patients undergoing haplo-HSCT. The study targets a niche yet critical segment of the hematologic oncology market, particularly focusing on high-risk AML patients who have limited treatment options. The findings could influence clinical practices and donor selection criteria, potentially leading to improved patient outcomes and market positioning for therapies that enhance transplantation success rates. Given the increasing prevalence of AML and the demand for effective GVHD prophylaxis, successful outcomes may enhance the competitive landscape for related therapies and donor management strategies.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

The Effect of the Parous Female and Young Male Donor on the Outcomes of GVHD Prophylaxis Underwent the Combined Treatment of ATG and PTCy for Haplo-HSCT: a Prospective, Multi-center, Cohort Study

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT06686173

Status

NOT_YET_RECRUITING

Phase

Not yet recruiting

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Executive brief

Investment-Ready Snapshot

This prospective, multicenter cohort study sponsored by Shanghai General Hospital aims to evaluate the impact of donor characteristics (parous female vs. young male) on GVHD prophylaxis outcomes in high-risk acute myeloid leukemia (AML) patients undergoing haplo-HSCT. The study targets a niche yet critical segment of the hematologic oncology market, particularly focusing on high-risk AML patients who have limited treatment options. The findings could influence clinical practices and donor selection criteria, potentially leading to improved patient outcomes and market positioning for therapies that enhance transplantation success rates. Given the increasing prevalence of AML and the demand for effective GVHD prophylaxis, successful outcomes may enhance the competitive landscape for related therapies and donor management strategies.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 07, 2025
Internal syncJun 18, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06686173

Indication

High-Risk Acute Myeloid Leukemia

Modality

combination therapy

Target

Graft-versus-host disease (GVHD) prophylaxis through the combination of antithymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) in haploidentical peripheral blood stem cell transplantation (haplo-HSCT).

Intervention

None-placebo, non-intervention study, donor selection

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.